|
1
|
Russo F, Linsalata M and Orlando A:
Probiotics against neoplastic transformation of gastric mucosa:
Effects on cell proliferation and polyamine metabolism. World J
Gastroenterol. 20:13258–13272. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang W, Sun XW, Li CF, Lv L, Li YF, Chen
YB, Xu DZ, Kesari R, Huang CY, Li W, et al: Comparison of the 6th
and 7th editions of the UICC TNM staging system for gastric cancer:
Results of a Chinese single-institution study of 1,503 patients.
Ann Surg Oncol. 18:1060–1067. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bringeland EA, Wasmuth HH, Fougner R,
Mjønes P and Grønbech JE: Impact of perioperative chemotherapy on
oncological outcomes after gastric cancer surgery. Br J Surg.
101:1712–1720. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bahudhanapati H, Bhattacharya S and Wei S:
Evolution of vertebrate Adam genes; Duplication of
testicular Adams from ancient Adam9/9-like loci. PLoS
One. 10:e01362812015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kelwick R, Desanlis I, Wheeler GN and
Edwards DR: The ADAMTS (A Disintegrin and Metalloproteinase with
Thrombospondin motifs) family. Genome Biol. 16:1132015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Amendola RS, Martin AC, Selistre-de-Araújo
HS, Paula-Neto HA, Saldanha-Gama R and Barja-Fidalgo C: ADAM9
disintegrin domain activates human neutrophils through an autocrine
circuit involving integrins and CXCR2. J Leukoc Biol. Mar
12–2015.(Epub ahead of print). pii: jlb.3A0914-455R. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peduto L: ADAM9 as a potential target
molecule in cancer. Curr Pharm Des. 15:2282–2287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Quach HT, Hirano S, Fukuhara S, Watanabe
T, Kanoh N, Iwabuchi Y, Usui T and Kataoka T: Irciniastatin A
induces potent and sustained activation of extracellular
signal-regulated kinase and thereby promotes ectodomain shedding of
tumor necrosis factor receptor 1 in human lung carcinoma A549
cells. Biol Pharm Bull. 38:941–946. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jones JC, Rustagi S and Dempsey PJ: ADAM
proteases and gastrointestinal function. Annu Rev Physiol.
78:243–276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu CM, Hsieh CL, He YC, Lo SJ, Liang JA,
Hsieh TF, Josson S, Chung LW, Hung MC and Sung SY: In vivo
targeting of ADAM9 gene expression using lentivirus-delivered shRNA
suppresses prostate cancer growth by regulating REG4 dependent cell
cycle progression. PLoS One. 8:e537952013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li J, Ji Z, Qiao C, Qi Y and Shi W:
Overexpression of ADAM9 promotes colon cancer cells invasion. J
Invest Surg. 26:127–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Micocci KC, Martin AC, Montenegro CF,
Durante AC, Pouliot N, Cominetti MR and Selistre-de-Araujo HS:
ADAM9 silencing inhibits breast tumor cell invasion in vitro.
Biochimie. 95:1371–1378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen CM, Hsieh YH, Hwang JM, Jan HJ, Hsieh
SC, Lin SH and Lai CY: Fisetin suppresses ADAM9 expression and
inhibits invasion of glioma cancer cells through increased
phosphorylation of ERK1/2. Tumour Biol. 36:3407–3415. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kiselev FL: MicroRNA and cancer. Mol Biol.
48:232–242. 2014.(In Russian).
|
|
15
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Connerty P, Ahadi A and Hutvagner G: RNA
Binding proteins in the miRNA pathway. Int J Mol Sci. 17:E312015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cai J, Xu L, Cai Z, Wang J, Zhou B and Hu
H: MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by
targeting epidermal growth factor receptor. Mol Med Rep.
12:1549–1555. 2015.PubMed/NCBI
|
|
18
|
Xing B and Ren C: Tumor-suppressive
miR-99a inhibits cell proliferation via targeting of TNFAIP8 in
osteosarcoma cells. Am J Transl Res. 8:1082–1090. 2016.PubMed/NCBI
|
|
19
|
Zou Z, Ni M, Zhang J, Chen Y, Ma H, Qian
S, Tang L, Tang J, Yao H, Zhao C, et al: miR-30a can inhibit
DNA replication by targeting RPA1 thus slows down the proliferation
of cancer cells. Biochem J. 473:2131–2139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang PF, Sheng LL, Wang G, Tian M, Zhu
LY, Zhang R, Zhang J and Zhu JS: miR-363 promotes proliferation and
chemo-resistance of human gastric cancer via targeting of FBW7
ubiquitin ligase expression. Oncotarget. 7:35284–35292.
2016.PubMed/NCBI
|
|
21
|
Wang J, Chen X, Li P, Su L, Yu B, Cai Q,
Li J, Yu Y, Liu B and Zhu Z: CRKL promotes cell proliferation in
gastric cancer and is negatively regulated by miR-126. Chem Biol
Interact. 206:230–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Chen X, Su L, Li P, Cai Q, Liu B,
Wu W and Zhu Z: MicroRNA-126 inhibits cell proliferation in gastric
cancer by targeting LAT-1. Biomed Pharmacother. 72:66–73. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang Z, Wang R, Zhang T and Dong X:
MicroRNA-126 regulates migration and invasion of gastric cancer by
targeting CADM1. Int J Clin Exp Pathol. 8:8869–8880.
2015.PubMed/NCBI
|
|
24
|
Chen H, Li L, Wang S, Lei Y, Ge Q, Lv N,
Zhou X and Chen C: Reduced miR-126 expression facilitates
angiogenesis of gastric cancer through its regulation on VEGF-A.
Oncotarget. 5:11873–11885. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Feng R, Chen X, Yu Y, Su L, Yu B, Li J,
Cai Q, Yan M, Liu B and Zhu Z: miR-126 functions as a tumour
suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wong JC, Hasan MR, Rahman M, Yu AC, Chan
SK, Schaeffer DF, Kennecke HF, Lim HJ, Owen D and Tai IT:
Nucleophosmin 1, upregulated in adenomas and cancers of the colon,
inhibits p53-mediated cellular senescence. Int J Cancer.
133:1567–1577. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wet M, Liu JY, Lv X, Nei H, Liu BY, Zhu
ZG, Yang ZY and Gu QL: Preparation of PHF10 antibody and analysis
of PHF10 expression gastric cancer tissues. Xi Bao Yu Fen Zi Mian
Yi Xue Za Zhi. 26:874–876. 2010.PubMed/NCBI
|
|
28
|
Li X, Zhang Y, Zhang H, Liu X, Gong T, Li
M, Sun L, Ji G, Shi Y, Han Z, et al: miRNA-223 promotes gastric
cancer invasion and metastasis by targeting tumor suppressor
EPB41L3. Mol Cancer Res. 9:824–833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Feng L, Xie Y, Zhang H and Wu Y: miR-107
targets cyclin-dependent kinase 6 expression, induces cell cycle G1
arrest and inhibits invasion in gastric cancer cells. Med Oncol.
29:856–863. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamada D, Ohuchida K, Mizumoto K, Ohhashi
S, Yu J, Egami T, Fujita H, Nagai E and Tanaka M: Increased
expression of ADAM 9 and ADAM 15 mRNA in pancreatic
cancer. Anticancer Res. 27:793–799. 2007.PubMed/NCBI
|
|
31
|
Zhang J, Chen N, Qi J, Zhou B and Qiu X:
HDGF and ADAM9 are novel molecular staging biomarkers, prognostic
biomarkers and predictive biomarkers for adjuvant chemotherapy in
surgically resected stage I non-small cell lung cancer. J Cancer
Res Clin Oncol. 140:1441–1449. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tao K, Qian N, Tang Y, Ti Z, Song W, Cao D
and Dou K: Increased expression of a disintegrin and
metalloprotease-9 in hepatocellular carcinoma: Implications for
tumor progression and prognosis. Jpn J Clin Oncol. 40:645–651.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS,
Shin YK, Zhang X, Park KH, Park SW, Chung HC, et al: The effect of
disintegrin-metalloproteinase ADAM9 in gastric cancer progression.
Mol Cancer Ther. 13:3074–3085. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carl-McGrath S, Lendeckel U, Ebert M,
Roessner A and Röcken C: The disintegrin-metalloproteinases ADAM9,
ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol.
26:17–24. 2005.PubMed/NCBI
|
